ReportWire

Tag: Cell Biology

  • Immune cells have a backup mechanism

    Immune cells have a backup mechanism

    [ad_1]

    Newswise — The enzyme TBK1 is an important component of the innate immune system that plays a critical role in the defense against viruses. Upon mutation-induced loss of TBK1 function, patients show an increased susceptibility to viral infections. Strikingly, if TBK1 is not expressed at all, this clinical effect is not seen. The mechanism behind this supposed discrepancy has now been elucidated by researchers led by Prof. Martin Schlee from the University Hospital Bonn and the Cluster of Excellence ImmunoSensation2 at the University of Bonn. The study was published in the journal Frontiers in Immunology.

    In the human body, viral particles are recognized by so called pattern recognition receptors (PRRs) situated within the cell or on the cell surface. Upon activation, a signaling cascade is initialized which ultimately results in the production and release of signaling molecules such as interferons and cytokines. These messenger molecules alert neighboring immune cells and point out the viral infection, inducing an immune reaction.

    Part of this signaling cascade is the TANK Binding Kinase 1 (TBK1). If viral particles are detected by PRRs, TBK1 is activated. TBK1 in turn activates two transcription factors which travel into the nucleus where they induce the transcription of interferon and cytokine genes.

    Susceptibility to viral infections

    Point-mutations in the TBK1 gene may induce a loss of function of TBK1. In humans, this manifests itself in clinical susceptibility to viral infections. Strikingly, this effect is not to be observed if TBK1 is not expressed and entirely lacking in the cell. “Surprisingly, a complete absence of TBK1 expression in humans is not associated with a reduced antiviral response,” says Prof. Martin Schlee of the Institute of Clinical Chemistry and Clinical Pharmacology at the University Hospital Bonn. Until now, it was unclear why a complete loss of TBK1 expression is better tolerated in terms of immunocompetence than a mutation of TBK1 affecting the kinase function.

    The Bonn researchers have now been able to provide an explanation for these previously unexplained observations. “A second enzyme that is very similar to TBK1 plays an important role in this: the IkB kinase epsilon, or IKKepsilon for short,” explains Dr. Julia Wegner, first author of the study. Just like TBK1, IKKepsilon acts downstream of PRRs and controls the expression of interferons. The two proteins are also very similar in structure, with more than 60 percent sequence homology. A novel finding is that TBK1 has a direct effect on IKKepsilon. “In myeloid cells, we could show that TBK1 regulates the expression of the related kinase IKKepsilon,” adds Dr. Wegner.

    No half measures

    TBK1 reduces the stability of IKKepsilon. This process is independent of the protein’s enzymatic function. “Accordingly, TBK1 that is nonfunctional due to point mutation is still able to destabilize IKKepsilon,” explains Prof. Gunther Hartmann, director of the Institute of Clinical Chemistry and Clinical Pharmacology and spokesperson of the ImmunoSensation2 Cluster of Excellence. “This leads to a continuous degradation of the kinase IKKepsilon in human immune cells.”

    Therefore, loss of TBK1 expression leads to an increased abundance of IKKepsilon. This mechanism ensures that an antiviral immune response can occur despite the absence of TBK1. Loss of function of TBK1 induced by point mutations, on the other hand, does not prevent destabilization and degradation of IKKepsilon, so that ultimately both factors are not available for viral defense. Increased susceptibility to viral infections is the result.

    Weapons of a virus

    In a healthy organism, increased amounts of IKKepsilon can thus compensate for the loss of TBK1. This becomes particularly important when viruses specifically seek to eliminate the body’s own defenses. Herpes simplex virus 1 (HSV-1), human immunodeficiency virus (HIV) but also severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are able to specifically induce TBK1 degradation. Also, several bacterial species are capable of causing the degradation of TBK1. “Our data clearly show that human immune cells have an important backup mechanism,” explains Dr. Wegner. “They are able to maintain an effective antiviral response even when pathogen-induced degradation of TBK1 occurs. Furthermore, the mechanism also takes effect in the case of genetic loss of TBK1.”

    Publication: Wegner Julia, Hunkler Charlotte, Ciupka Katrin, Hartmann Gunther, Schlee Martin (2023); Increased IKKepsilon protein stability ensures efficient type I interferon responses in conditions of TBK1 deficiency; Frontiers in Immunology , Vol. 14; DOI: 10.3389/fimmu.2023.1073608

    [ad_2]

    University of Bonn

    Source link

  • With $13M, UIC scientists will study lung inflammation mechanisms

    With $13M, UIC scientists will study lung inflammation mechanisms

    [ad_1]

    Newswise — Researchers from the University of Illinois Chicago hope to learn more about how the human immune system is regulated by the endothelium in lung tissue, thanks to a $13 million, multi-project Program Project Grant award from the National Heart, Lung, and Blood Institute.

    The researchers hope that the projects will lead to new avenues for research and treatments to help patients who suffer from conditions like chronic obstructive pulmonary disorder, pulmonary fibrosis and acute respiratory distress disorder, a common and serious complication of COVID-19.

    Conditions like these are known to be exacerbated by the body’s own immune response, such as when the inflammation meant to fight infections or heal injuries spirals out of control and winds up inflicting harm.

    The researchers think that these inflammatory conditions may be common in the lungs because of unique endothelial cells, which line blood vessels and shield the lungs from trauma and bacterial or viral infections.

    “Targeted therapies remain an urgent unmet need. It is now becoming increasingly clear that the lung endothelium is a complex monolayer, an organ itself,” said Dolly Mehta, UIC professor and interim head of the Department of Pharmacology and Regenerative Medicine at the College of Medicine and the program director for the grant.  

    “Studying this enigmatic immune regulatory function of lung endothelium is crucial for understanding how endothelial cells control immunity and defensive function of the lungs,” she said.

    The research team consists of six investigators who will lead three separate project grants and three separate cores.

    Mehta is also the principal investigator for one of the projects, for $2.2 million, which supports research on a protein receptor in endothelial cells that promotes lung integrity.

    Asrar Malik, professor of pharmacology and regenerative medicine, and Dr. Jalees Rehman, professor and head of the Department of Biochemistry and Molecular Genetics, will lead the other two project grants.

    Malik’s lab will look at an enzyme called E3 ligase that influences the integrity of the lining of the blood vessels and the genes that activate the enzyme. Rehman’s lab will look at how mitochondria in endothelial cells can be leveraged to prevent out-of-control inflammation. The awards are $1.8 million and $2.2 million, respectively.

    “We know that in tissues like those found in the lung, heart and brain, the blood vessels present a unique and complicated immune environment, and we know that there is an interconnectedness between all the many cellular processes. The idea of this multi-project grant is to help create an infrastructure for collaboration among researchers looking at these various mechanisms,” Mehta said.

    Konstantinos Chronis, assistant professor of biochemistry and molecular genetics, will lead the project’s epigenetics and transcriptomics core. Gary Mo, assistant professor of pharmacology and regenerative medicine, will lead the cellular imaging core. Yoshikazu Tsukasaki, a research assistant professor also from the department of pharmacology and regenerative medicine, will lead the intravital imaging and physiology core.

    [ad_2]

    University of Illinois Chicago

    Source link

  • Acid glia in REM sleep: Stronger acid response in epileptic mice

    Acid glia in REM sleep: Stronger acid response in epileptic mice

    [ad_1]

    Newswise — Researchers at Tohoku University have shown that astrocytes – star-shaped glial cells that control the local ionic and metabotropic environment of the brain – exhibit an acid response with REM sleep in mice. They theorize that the acid response could be the underlying drive for specific information processing and generating plasticity during sleep. 

    They further discovered that the REM response in astrocytes intensified in the epileptic brain, meaning studying brain environmental changes associated with REM sleep could potentially be employed as a biomarker for the severity of epileptogenesis. 

    The findings were detailed in the journal Brain on March 3, 2023. 

    Neurons are undoubtedly responsible for information processing in the brain. Astrocytes were not thought to be an essential component of the neural information circuit. However, recent findings suggest that the state of the mind, such as consciousness, sleep, memory formation, and meta-plasticity may all be controlled by astrocytes’ actions. 

    To understand the role of astrocytes in brain function, fluorescent sensor proteins were genetically expressed in the astrocytes of mice. The researchers implanted an optical fiber into the mice’s lateral hypothalamus, a part of the brain vital for controlling our state of being asleep or awake and whole-body metabolism. 

    Excitation light was sent through this fiber and the emitted fluorescence signals were recorded. Using a newly devised method, the researchers dissected the calcium concentration and pH of the astrocytes and the local brain blood volume changes from the recorded optical signals. 

    A clear change in the optical signals associated with REM sleep was observed. A calcium decrease, pH decrease (i.e., acidification), and increase in local brain blood volume occurred. The researchers identified that acidification and blood volume changes produce a strong effect on the optical signals; thus, many of the previous studies using fiber photometry could have misinterpreted their recorded data. 

    Acidification was especially unexpected, as the intracellular solution of cells is highly buffered for pH. Strong acidification occurs upon ischemia but changes in pH were not assumed to occur under physiological conditions. This astrocyte acidification may drive the amplification of synaptic signals and may underlie memory formation during REM sleep. 

    Interestingly, changes in the local brain environment detected with the optical recordings preceded the signature change of the ensemble neuronal electrical activity detected with electroencephalogram by nearly 20 seconds. This suggests that astrocytes and vascular changes control the state of neuronal activity. Transition to REM sleep can also be predicted from these local brain environmental changes. 

    “During REM sleep, prior experiences are sorted and remembered or forgotten, and this process is likely perceived as dreams,” says Professor Ko Matsui of the Super-network Brain Physiology lab at Tohoku University, who led the research. “Acidification in astrocytes may control the likelihood of plasticity to occur in the neural circuits.” 

    The researchers further studied how the properties of REM sleep change with epilepsy. Repeated stimulus to a mouse’s hippocampus produces a brain prone to hyperactivity and this “kindling” method has been used as a model of epileptogenesis. After kindling, spontaneously occurring REM sleep episodes were recorded. Surprisingly, very little astrocytic calcium decreases and local brain blood volume increases occurred with REM sleep, and a strong acid response was recorded from astrocytes. 

    “Our previous study has shown an increased acid response of astrocytes associated with intensified epileptic seizures,” says the lead study investigator, Dr. Yoko Ikoma. “Information is transmitted and processed with electrical signals in neurons. The pH of astrocytes may have control over these neuronal activities both in physiology and in disease.” 

    Monitoring of the bulk pH and local brain blood flow is possible in humans using fMRI. Ikoma says that these local brain environmental changes associated with REM sleep can potentially be used to diagnose the severity of epilepsy in human patients. “A therapeutic strategy designed to control astrocytes’ pH could potentially be used for preventing exacerbation of epilepsy.”

    [ad_2]

    Tohoku University

    Source link

  • Thrive Bioscience Debuts New Cell Imaging Capabilities and CellAssist Software Release 4.0 to Advance Laboratory Automation

    Thrive Bioscience Debuts New Cell Imaging Capabilities and CellAssist Software Release 4.0 to Advance Laboratory Automation

    [ad_1]

    Newswise — SAN DIEGOFeb. 27, 2023 /PRNewswire/ — Thrive Bioscience Inc., an innovative provider of automated live cell imaging instruments and software, debuts a new integrated suite of unique and exciting capabilities, including Release 4.0 of its CellAssist software, that significantly advances the field of live cell imaging.

    Thrive Bioscience Debuts New Cell Imaging Capabilities and CellAssist Software Release 4.0 to Advance Lab Automation

    Thrive’s CellAssist family of networkable instruments now provides unprecedented new capabilities for researchers to automatically capture thousands of time-series images with 100+ focal planes on 1 to 50 cell culture plates within a controlled environment. Imaging modes include phase contrast and bright-field at 4x, 10x, and 20x in 6-well to 384-well round bottom and flat bottom plates.

    The CellAssist family includes a benchtop model, a robotic 50-plate model, and advanced software that produces comprehensive databases of high-quality images, metrics, and documentation that provide researchers groundbreaking insights into cell and tissue dynamics.

    New CellAssist family product hardware and software capabilities include:

    • Imaging a 4mm z-range with 100+ focal planes, each 2 µm to 50 µm apart (user-selectable)
    • 40% faster image capture rates (gigabytes of images in minutes)
    • Image correction for physical variations in cell culture plates
    • Imaging in round bottom 6-well to 384-well plates
    • Spheroid area and volume calculation toolkit

    “The CellAssist family of products, including and software Release 4.0, offer unique imaging capabilities that will vastly improve organoid imaging, IVF imaging, viral plaque assays, gene editing (CRISPR), and stem cell production for researchers,” explained Thomas Farb-Horch, CEO of Thrive.

    Thrive unveiled these new capabilities at the Society for Laboratory Automation and Screening’s annual meeting in San Diego, February 26 – 28, 2023, and the family of products is set to be launched following the conference.

    About Thrive Bioscience
    Thrive Bioscience, located in the Boston area, is an innovative provider of instruments with integrated software tools for live cell, stem cell, and tissue imaging, analytics, and automation. Thrive’s instruments enable reproducible cell culture imaging and breakthrough insights into cell dynamics by integrating microscopy and robotics to automatically capture and build databases of terabytes of data. Additional information: www.thrivebio.com.

    Thrive Bioscience and CellAssist are registered trademarks of Thrive Bioscience, Inc. Copyright © 2023 Thrive Bioscience, Inc. All Rights Reserved.

    [ad_2]

    Thrive Bioscience, Inc.

    Source link

  • Could a naturally occurring amino acid lead us to a cure for COVID-19?

    Could a naturally occurring amino acid lead us to a cure for COVID-19?

    [ad_1]

    Newswise — After more than two years since its discovery, six million deaths, and half a billion reported cases, there is still no effective cure for COVID-19. Even though vaccines have lowered the impact of outbreaks, patients that contract the disease can only receive supportive care while they wait for their own body to clear the infection.

    A promising COVID-19 treatment strategy that has been gaining traction lately is targeting angiotensin-converting enzyme 2 (ACE2). This is a receptor found on the cell membrane that allows entry of the virus into the cell due to its high affinity for SARS-CoV-2’s spike protein. The idea is that reducing the levels of ACE2 on the membrane of cells could be a way to prevent the virus from entering them and replicating, thereby lowering its infectious capabilities.

    In a recent study published in PLOS ONE, a team of scientists including Associate Professor Shun-Ichiro Ogura from Tokyo Institute of Technology, Japan, analyzed the potential of a natural amino acid called 5-Aminolevulinic acid (ALA) to reduce the expression of ACE2. This research was performed in collaboration with SBI Pharmaceuticals Co. Ltd.

    As the researchers explain in their paper, ALA had been identified in 2021 as a compound that seemed to reduce the infectivity of SARS-CoV-2. However, the underlying mechanisms that led to this phenomenon remained unknown, until now.

    The team hypothesized that the results of the 2021 study could be explained by an effect of ALA on the expression of ACE2. To test their hypothesis, they prepared human cell cultures, administered ACE2 on some of them, and compared the levels of ACE2 in treated cells versus control cells. As expected, the amount of available ACE2 in treated cells was significantly lower than in control cells.

    But the story doesn’t end there. Upon uptake, cells transform ALA into a molecule called protoporphyrin IX (PpIX) and subsequently into heme—a precursor of hemoglobin and other useful proteins. This hinted that the expression of ACE2 could be linked to the production of either of these compounds. Thus, the team checked the levels of PpIX and heme in cells treated with ALA. “We observed significant increases in the concentration of intracellular PpIX, suggesting that ALA was uptaken into the cell and converted into PpIX,” remarks Ogura, “However, only a slight increase in heme concentration was observed, which might be due to the lack of an iron source to convert PpIX into heme.”

    After introducing an iron source in the form of sodium ferrous citrate, the intracellular levels of heme increased significantly and the expression of ACE2 became even lower. These results suggest ACE2 expression is kept in check by heme production, the latter of which can be boosted by the co-administration of ALA and an iron source.

    Overall, this study sheds light on how ALA and the heme production pathway could form the basis of a cure for COVID-19. “We believe ALA could be developed into a potential anti-viral agent for SARS-CoV-2, which may play an important role in the eradication of the disease in a global scale in the near future,” concludes Dr. Ogura.

    Let us hope further studies can help us put an end to COVID-19 soon!

    [ad_2]

    Tokyo Institute of Technology

    Source link

  • Making engineered cells dance to ultrasound

    Making engineered cells dance to ultrasound

    [ad_1]

    Newswise — Let’s say you needed to move an individual cell from one place to another. How would you do it? Maybe some special tweezers? A really tiny shovel?

    The fact is that manipulating individual cells is a difficult task. Some work has been done on so-called optical tweezers that can push cells around with beams of light, but while they are good at moving a single cell around, they are not intended for manipulating larger numbers of cells.

    New research conducted at Caltech has created an alternative: air-filled proteins, produced by genetically engineered cells, that can be pushed around—along with the cells containing them—by ultrasound waves. A paper describing the work appears in the journal Science Advances.

    The work builds on previous work conducted in the lab of Mikhail Shapiro, professor of chemical engineering and medical engineering and investigator with the Howard Hughes Medical Institute.

    Shapiro has for years worked with gas vesicles derived from bacteria as an acoustic tag. These vesicles, which are air-filled capsules of protein, provide buoyancy to some species of aquatic bacteria. But they also have another useful quality: Because of their air-filled interiors, they show up quite strongly in ultrasound imagery. Shapiro’s discovery of this quality has led his lab to develop gas vesicles as a genetic marker for tracking the location of individual bacterial cells, and for observing gene-expression activity in mammalian cells deep inside the body.

    Now, Shapiro and his colleagues have shown that these vesicles can push and pull cells into specific locations under the influence of ultrasound. The phenomenon is very similar to how ultrasound in air can be used to suspend and/or move small, light objects. This is due to the fact that sound waves create pressure zones that act on objects in their vicinity. The physical properties of an object or material determine whether it will be attracted to a high-pressure zone or repulsed by it. Normal cells are pushed away from areas of higher pressure, but cells containing gas vesicles are attracted to them.

    “We’ve used these vesicles for imaging previously, and this time we’ve shown that we can actually use them as actuators so we can apply force to these objects using ultrasound,” says Di Wu (MS ’16, PhD ’21), a research scientist in Shapiro’s lab and the study’s lead author. “What this allows us to do is to move cells around in space using ultrasound and to be able to do so in a very selective manner.”

    Shapiro and Wu say there a few reasons you might want to be able to move cells around. For one, tissue engineering—the creation of artificial tissues for research or medical purposes—requires cells of specific types to be arranged in complex patterns. An artificial muscle might need multiple layers of muscle cells, cells that create tendons, and nerve cells, for example.

    Another case in which you might want to move cells around is in cell-based therapy, a field of medicine in which cells with desirable properties are introduced into the body.

    “You’re introducing engineered cells into the body, and they go all over the place to find their target,” Di says. “But with this technology, we potentially have a way to guide them to the desired location into the body.”

    As a demonstration, the team showed that cells containing gas vesicles can be forced to clump into a small ball, or arranged as thin bands, or pushed to the edges of a container. When they changed the ultrasound pattern, the cells “danced” to take up new positions. They also developed an ultrasound pattern that pushed the cells into the shape of the letter “R” in a gel that held them in that shape after it solidified. They call the resulting figure an “acoustic hologram.”

    Wu says one area where their research has the potential for immediate impact is in cell sorting, a process necessary for various kinds of biological and medical research.

    “A common way people sort cells now is to engineer them to express a fluorescent protein and then use a fluorescent-activated cell sorter (FACS),” he says. “That is a $300,000 piece of equipment that is bulky, often lives in a biosafety cabinet, and doesn’t sort cells very fast.”

    “In contrast, acousto-fluidic sorting can be done with a tiny little chip that costs maybe $10. The reason for this difference is that in fluorescent sorting, you have to separately measure the gene expression of the cells and then move them. This is done one cell at a time. With gas vesicle expression, the cell’s genetics are directly linked to the force that’s being applied to the cell. If they express gas vesicles, they will experience a different force, so we don’t need to separately check if they’re expressing gas vesicles and then move them; we can move them all at once. That greatly simplifies things.”

    The paper describing the research, titled “Biomolecular actuators for genetically selective acoustic manipulation of cells,” appears in the February 22 of Science Advances. Additional co-authors are former Caltech medical engineering PhD students Colin Cook (MS ’16, PhD ’19), who is now a staff scientist at City of Hope; and David R. Mittelstein (MS ’16, PhD ’20), who is now a resident physician at Scripps Health; former postdoctoral fellow David Maresca, who is now an assistant professor at Delft University of Technology, Netherlands; Caltech chemical engineering graduate student Maria Abundo and bioengineering graduate students Mengtong Duan, Justin Lee, and Shirin Shivaei; Dina Malounda of the Howard Hughes Medical Institute, Diego Baresch of the University of Bordeaux in France; Zhichao Ma of the Max Planck Institute for Intelligent Systems in Stuttgart, Germany; Tian Qiu of the University of Stuttgart, Germany; and Peer Fischer of the Max Planck Institute for Medical Research and Heidelberg University in Heidelberg, Germany.

    Funding for the research was provided by the National Institutes of Health, the U.S. Army’s Institute for Collaborative Biotechnologies, the David and Lucile Packard Foundation, and the Pew Charitable Trust. Mikhail Shapiro is an affiliated faculty member with the Tianqiao and Chrissy Chen Institute for Neuroscience at Caltech.

    [ad_2]

    California Institute of Technology

    Source link

  • CHOP Researchers Identify Molecules that Optimize Immune Presentation of Antigens across the Human Population

    CHOP Researchers Identify Molecules that Optimize Immune Presentation of Antigens across the Human Population

    [ad_1]

    Newswise — Philadelphia, February 24, 2023—Researchers at Children’s Hospital of Philadelphia (CHOP) have identified variants of a chaperone molecule that optimizes the binding and presentation of foreign antigens across the human population, which could open the door to numerous applications where robust presentation to the immune system is important, including cell therapy and immunization. The findings were published today in Science Advances. 

    Class I major histocompatibility complex (MHC-I) proteins are found on the surface of cells from all jawed vertebrates and play an essential role in the immune system. The MHC-I displays peptide fragments of proteins from within the cell on the cell surface, effectively “presenting” them to the immune system, which is constantly scanning the body for foreign or toxic antigens. When foreign peptides are identified, they trigger a cascade that allows cytotoxic T cells to eliminate intruders.

    For a peptide to be presented to the immune system, it needs to be loaded on a folded MHC-I protein. Several molecules facilitate this process, including proteins known as molecular chaperones, which assist with MHC-I folding. Tapasin and a similar molecule known as TAPBPR are both molecular chaperones that facilitate MHC-I folding and peptide loading. Because TAPBR functions independently outside of the peptide-loading complex, it is well-suited for clinical applications that involve peptide exchange, such as loading immunogenic peptides on MHC-I molecules and generating libraries to detect T-cells that recognize peptides or antigens from infected or cancerous cells.

    However, TAPBPR-mediated peptide exchange has thus far only worked for a limited set of common allotypes of human MHC-I, known as human leukocyte antigen (HLA), which has limited wider use of these technologies in biomedical applications. Over time, HLA subtypes, which include HLA-A, HLA-B, and HLA-C, have evolved such that not all alleles interact equally well with TAPBPR. This has been a roadblock in developing and enhancing novel therapies with the help of molecular chaperones, as some HLA allotypes do not interact with these molecules. 

    To solve this problem, the CHOP researchers analyzed three different TAPBPR proteins: one from humans, one from chickens, and one from mice. They found that unlike human TAPBPR, chicken TAPBPR co-evolved with its class I genes, so that it maintains high affinity across MHC-I allotypes. In their analysis, they found that chicken TAPBPR was able to react with multiple HLA allotypes, many of which were not able to bind to human TAPBPR. They also demonstrated that TAPBPR stabilizes the empty MHC-I groove in an “open” conformation, boosting its affinity for peptide loading.

    Simultaneously, in close collaboration with researchers at the University of Illinois led by Erik Procko, PhD, the research team used deep mutational scanning to characterize the effects from 100s of point mutations on human TAPBPR and found a variant that mimics the chicken sequence. Like the chicken TAPBPR, this variant enhanced peptide exchange across a broad range of HLA types.

    “Although the highly polymorphic nature of MHC-I molecules makes it challenging to engineer ‘universal’ chaperones, our research team demonstrated that both a chicken ortholog of TAPBPR and a human variant with minor adjustments could enhance peptide exchange across multiple disease-relevant HLAs,” said senior author Nikolaos G. Sgourakis, PhD, Associate Professor in the Center for Computational and Genomic Medicine at Children’s Hospital of Philadelphia. “These TAPBPR orthologs could be utilized in various cancer immunotherapeutic settings to narrow the peptide repertoire and increase immunogenicity. The knowledge gained by our studies can guide the design of engineered TAPBPR variants with tailored HLA specificity and catalytic efficiency for peptide exchange applications both in vitroand in vivo.”

    This research was supported by funding from the National Institute of Allergy and Infectious Diseases (5R01AI143997) and National Institute of General Medical Sciences (5R35GM125034). 

    Yi Sun, Georgia F. Papadaki, Christine A. Devlin, Julia N. Danon, Michael C. Young, Trenton J. Winters, George M. Burslem, Erik Procko, and Nikolaos G. Sgourakis. “Xeno-interactions between MHC-I proteins and molecular chaperones enable ligand exchange on a broad repertoire of HLA allotypes,” Science Advances, February 24, 2023, DOI: 10.1126/sciadv.ade7151 

    #

    About Children’s Hospital of Philadelphia: A non-profit, charitable organization, Children’s Hospital of Philadelphia was founded in 1855 as the nation’s first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, the 595-bed hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. The institution has a well-established history of providing advanced pediatric care close to home through its CHOP Care Network, which includes more than 50 primary care practices, specialty care and surgical centers, urgent care centers, and community hospital alliances throughout Pennsylvania and New Jersey, as well as a new inpatient hospital with a dedicated pediatric emergency department in King of Prussia. In addition, its unique family-centered care and public service programs have brought Children’s Hospital of Philadelphia recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu.

    [ad_2]

    Children’s Hospital of Philadelphia

    Source link

  • How a New Blood-Vessel-on-a-Chip Can Help Researchers Further Understand Vascular Malformations

    How a New Blood-Vessel-on-a-Chip Can Help Researchers Further Understand Vascular Malformations

    [ad_1]

    Newswise — CHAPEL HILL, N.C. – Our bodies are made up of 60,000 miles of complex pipes that play a vital role in transporting nutrients throughout our bodies, performing waste disposal, and supplying our organs with fresh oxygen and blood.

    Several things can go wrong with this complex system, including vascular malformations (VMs), a group of rare genetic disorders that causes an abnormal formation of veins, arteries, capillaries, or lymphatic vessels at birth. VMs can interfere with the duties of our precious pipes by causing blockages, poor drainage, and the formation of cysts and tangles.

    To address a need for further study, William Polacheck, PhD, an assistant professor at the UNC-NCSU Joint Department of Biomedical Engineering and the Department of Cell Biology and Physiology, and his team spanning across the UNC School of Medicine, have developed a model that mimics VMs that are specifically caused by a mutation of PIK3CA — a gene that has been implicated in multiple types of lymphatic, capillary, and venous malformations.

    Their work was published in Science Advances, an open access multidisciplinary journal from the American Association for the Advancement of Science (AAAS).

    “There are number of ‘chicken and the egg problems’ of the PIK3CA mutation,” said Polacheck. “Is it causing something else to go wrong? Or is there something else in the environment causing the mutation to have more severe effects? Working in a much more controlled environment, such as a microfluidic model, allows us to isolate and figure out how the genetics of the disease relate to what’s happening in the cells.”

    VMs are caused by mutations in the genes that direct the development of the vasculature throughout the body. Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) is one of those genes. Activating mutations in PIK3CA commonly contribute to malformations of the smaller blood vessels, causing blood to pool underneath the skin.

    This specific type of vascular malformation is usually discovered at birth. These diseases start as the baby is developing. Since there are a multitude of changes happening at this point in the child’s development, it can be difficult condition for researchers to study.

    Julie Blatt, MD, professor of pediatric hematology-oncology in the UNC Department of Pediatrics, saw the need for a new approach to model the disease, which affects a majority of her patients. She has had a long-standing interest in clinical management of patients with vascular malformations, as well as an interest in repurposing cancer drugs for the disease. Impressed with his prior manuscripts, Dr. Blatt picked up the phone and cold-called Polacheck, who is a biomedical engineer by trade, to ask if he could create a microfluidic model of PIK3CA-specific vascular malformations.

    “I think the transdisciplinary aspect keeps the possibility of application to patients at the forefront, said Dr. Blatt. “The Polacheck lab has prioritized introduction of genetic mutations that are relevant to patients and to studying drugs which we know or think will have benefit.”

    Around the same time, Wen Yih Aw, PhD, was working as a postdoctoral researcher at UNC Catalyst, a research group focused on understanding rare diseases in the Eshelman School of Pharmacy. Aw was collaborating with the Polacheck lab on a vascular Ehlers Danlos Syndrome project. Eventually, Aw joined the Polacheck lab and used her molecular biology expertise to help develop the VMs model.

    In addition to Dr. Blatt and Aw, the lab has an on-going collaboration with Boyce Griffith, PhD in the Department of Mathematics and the Computational Medicine Program at the UNC College of Arts and Sciences, who is helping with analyzing the structures of the networks.

    “All those pieces were necessary to complete the work,” said Polacheck. “It does say something about UNC-Chapel Hill because there were multiple departments across campus involved. There were no barriers whatsoever to working together on this project.”

    Microfluidic models are incredibly small – about the size of a millimeter – three-dimensional devices that can be used to control or simulate the environment within the body. In this case, a small piece of blood vessel composed of healthy human endothelial cells or endothelial cells expressing the PIK3CA mutation is centered inside of the device. From there, the researchers can look into the process of vascular formation, and introduce specific chemicals and mechanical forces to the model to simulate the conditions of the body. They observed formation of enlarged and irregular vasculature with the introduction of PIK3CA mutation.

    To confirm whether or not their model accurately portrays the manifestation of the disease, the team next conducted a drug efficacy study.

    There are two drugs currently used for the treatment of vascular malformations: rapamycin and alpelisib. The latter is a newly discovered PIK3CA-specific inhibitor recently approved by the FDA to treat certain types of breast cancer and PIK3CA-related overgrowth spectrum. So far, pre-clinical studies in mouse models and in patients have shown that alpelisib is more effective in reversing vascular malformation defects.

    After selecting the two drugs, Polacheck and Aw applied the treatment to their devices. The study was a success.

    “The blood vessels used to be really dilated and large,” said Aw, first author of the study. “By imaging the vessels before and after treating with drugs, we observed the vessels shrink and, more or less, revert it back to a normal shape and function. We were very excited to be able to replicate some of the results in vitro with the model we built.”

    Moving forward, Aw and Polacheck are looking to replicate the finding in tissues from vascular malformation patients, especially those who don’t have the PIK3CA mutation or don’t have clear genetic information. Their model can now be used to evaluate new medications or to perform synergistic drug studies.

    Now that they know that their model works, Aw and Polacheck plan to use it to study the behavior of the mutated cells overtime, as well as how the mutation affects malformations of the lymphatic tissue.

    The disease initially begins with an individual cell that acquires the PIK3CA mutation. Then, much like a chain reaction, the effects of the mutation in that one cell spreads to the surrounding cells until the malformation is fully formed. As their model currently stands, the lab cannot mimic that natural process.

    Aw is currently working on a new and different approach for a microfluidic model. She aims to create a platform that will allow them to start with cells that are healthy, and then “flip on” the mutation, and watch it progress across the tissue of interest. Ultimately, it will help them understand how the mutation is able to affect other cells and move throughout space.

    Vascular malformations can also occur in lymphatic tissue. As opposed to blood vessels, lymphatic vessels have a duty to recycle excess fluid throughout the body and acts as a superhighway for immune cells to get to sites of infection. Very little is known about the basic cell biology of lymphatic endothelial cells, so Polacheck is hoping to do a study that is similar to his most recent one.

    “The outputs are slightly different because the function of the lymphatics is different from blood vessels,” said Polacheck. “By comparing and contrasting what happens on the blood side and the lymphatic side, we will also be able to learn something about the basic biology of those two types of tissues.”

    [ad_2]

    University of North Carolina Health Care System

    Source link

  • Evolution: Miniproteins appeared “from nowhere”

    Evolution: Miniproteins appeared “from nowhere”

    [ad_1]

    Newswise — Every biologist knows that small structures can sometimes have a big impact: Millions of signaling molecules, hormones, and other biomolecules are bustling around in our cells and tissues, playing a leading role in many of the key processes occurring in our bodies. Yet despite this knowledge, biologists and physicians long ignored a particular class of proteins – their assumption being that because the proteins were so small and only found in primates, they were insignificant and functionless. The discoveries made by Professor Norbert Hübner at the Max Delbrück Center and Dr. Sebastiaan van Heesch at the Princess Máxima Center for Pediatric Oncology in the Netherlands changed this view a few years ago: “We were the first to prove the existence of thousands of new microproteins in human organs,” says Hübner.

    In a new paper published in Molecular Cell, the team led by Hübner and van Heesch now describe how they systematically studied these miniproteins, and what they learned from them: “We were able to show which genome sequences the proteins are encoded in, and when DNA mutations occurred in their evolution,” explains Dr. Jorge Ruiz-Orera, an evolutionary biologist in Hübner’s lab and one of the paper’s three lead authors, who work at the Max Delbrück Center and the German Center for Cardiovascular Research (DZHK). Ruiz-Orera’s bioinformatic gene analyses revealed that most human microproteins developed millions of years later in the evolutionary process than the larger proteins currently known to scientists.

    Yet the huge age gap doesn’t appear to prevent the proteins from “talking” to each other. “Our lab experiments showed that the young and old proteins can bind to each other – and in doing so possibly influence each other,” says lead author Dr. Jana Schulz, a researcher in Hübner’s team and at the DZHK. She therefore suspects that, contrary to long-held assumptions, the microproteins play a key role in a variety of cellular functions. The young proteins might also be heavily involved in evolutionary development thanks to comparatively rapid “innovations and adaptations.” “It’s possible that evolution is more dynamic than previously thought,” says van Heesch.

    Proteins only found in humans

    The researchers were surprised to find that the vastly younger microproteins could interact with the much older generation. This observation came from experiments performed using a biotechnical screening method developed at the Max Delbrück Center in 2017. In collaboration with Dr. Philipp Mertins and the Proteomics Platform, which the Max Delbrück Center operates jointly with the Berlin Institute of Health at Charité (BIH), the miniproteins were synthesized on a membrane and then incubated with a solution containing most of the proteins known to exist in a human cell. Sophisticated experimental and computer-aided analyses then allowed the researchers to identify individual binding pairs. “If a microprotein binds to another protein, it doesn’t necessarily mean that it will influence the workings of the other protein or the processes that the protein is involved in,” says Schulz. However, the ability to bind does suggest the proteins might influence each other’s functioning. Initial cellular experiments conducted at the Max Delbrück Center in collaboration with Professors Michael Gotthardt and Thomas Willnow confirm this assumption. This leads Ruiz-Orera to suspect that the microproteins “could influence cellular processes that are millions of years older than they are, because some old proteins were present in the very earliest life forms.”

    Unlike the known, old proteins that are encoded in our genome, most microproteins emerged more or less “out of nowhere – in other words, out of DNA regions that weren’t previously tasked with producing proteins,” says Ruiz-Orera. Microproteins therefore didn’t take the “conventional” and much easier route of being copied and derived from existing versions. And because these small proteins only emerged during human evolution, they are missing from the cells of most other animals, such as mice, fish and birds. These animals, however, have been found to possess their own collection of young, small proteins.

    The smallest proteins so far

    During their work, the researchers also discovered the smallest human proteins identified to date: “We found over 200 super-small proteins, all of which are smaller than 16 amino acids,” says Dr. Clara Sandmann, the study’s third lead author. Amino acids are the sole building blocks of proteins. Sandmann says this raises the question of how small a protein can be – or rather, how big it must be to be able to function. Usually, proteins consist of several hundred amino acids.

    The small proteins that were already known to scientists are known as peptides and function as hormones or signal molecules. They are formed when they split off from larger precursor proteins. “Our work now shows that peptides of a similar size can develop in a different way,” says Sandmann. These smallest-of-the-small proteins can also bind very specifically to larger proteins – but it remains unclear whether they can become hormones or similar: “We don’t yet know what most of these microproteins do in our body,” says Sandmann.

    Yet the study does provide an inkling of what the molecules are capable of: “These initial findings open up numerous new research opportunities,” says van Heesch. Clearly, the microproteins are much too important for researchers to keep ignoring them. Van Heesch says the biomolecular and medical research communities are very enthusiastic about these new findings. One conceivable scenario would be “that these microproteins are involved in cardiovascular disease and cancer, and could therefore be used as new targets for diagnostics and therapies,” says Hübner. Several U.S. biotech companies are already doing research in this direction. And the team behind the current paper also has big plans: Their study investigated 281 microproteins, but the aim now is to expand the experiments to include many more of the 7,000 recently cataloged microproteins – in the hope that this will reveal many as-yet-undiscovered functions.

     

    Further information

    Unchartered territory in the human genome

    Unknown miniproteins in the heart

    Hübner Lab

    Van Heesch Lab

     

    Literature

    Clara-L. Sandmann, Jana F. Schulz, Jorge Ruiz-Orera, et al. (2023): “Evolutionary origins and interactomes of human, young microproteins and small peptides translated from short open reading frames,” Molecular Cell, DOI: 10.1016/j.molcel.2023.01.023
     

    Downloads

    An evolutionarily young protein that arose de novo in Old World monkeys: The microprotein in the mitochondria (green) and in the nucleus (blue) was overexpressed in human cells. The yellow and pink areas show that the signal of the microprotein overlaps with the mitochondrial and nuclear signals. Photo: Clara Sandmann, MDC

     

    Max Delbrück Center

    The Max Delbrück Center for Molecular Medicine in the Helmholtz Association (Max Delbrück Center) is one of the world’s leading biomedical research institutions. Max Delbrück, a Berlin native, was a Nobel laureate and one of the founders of molecular biology. At the Center’s locations in Berlin-Buch and Mitte, researchers from some 70 countries analyze the human system – investigating the biological foundations of life from its most elementary building blocks to systems-wide mechanisms. By understanding what regulates or disrupts the dynamic equilibrium in a cell, an organ, or the entire body, we can prevent diseases, diagnose them earlier, and stop their progression with tailored therapies. Patients should benefit as soon as possible from basic research discoveries. The Max Delbrück Center therefore supports spin-off creation and participates in collaborative networks. It works in close partnership with Charité – Universitätsmedizin Berlin in the jointly run Experimental and Clinical Research Center (ECRC), as well as with the Berlin Institute of Health (BIH) at Charité and the German Center for Cardiovascular Research (DZHK). Founded in 1992, the Max Delbrück Center today employs 1,800 people and is funded 90 percent by the German federal government and 10 percent by the State of Berlin. www.mdc-berlin.de

    [ad_2]

    Max Delbruck Center for Molecular Medicine in the Helmholtz Association

    Source link

  • Extracts from two wild plants inhibit COVID-19 virus, study finds

    Extracts from two wild plants inhibit COVID-19 virus, study finds

    [ad_1]

    Newswise — Two common wild plants contain extracts that inhibit the ability of the virus that causes COVID-19 to infect living cells, an Emory University study finds. Scientific Reports published the results — the first major screening of botanical extracts to search for potency against the SARS-CoV-2 virus.

    In laboratory dish tests, extracts from the flowers of tall goldenrod (Solidago altissima) and the rhizomes of the eagle fern (Pteridium aquilinum) each blocked SARS-CoV-2 from entering human cells.

    The active compounds are only present in miniscule quantities in the plants. It would be ineffective, and potentially dangerous, for people to attempt to treat themselves with them, the researchers stress. In fact, the eagle fern is known to be toxic, they warn.

    “It’s very early in the process, but we’re working to identify, isolate and scale up the molecules from the extracts that showed activity against the virus,” says Cassandra Quave, senior author of the study and associate professor in Emory School of Medicine’s Department of Dermatology and the Center for the Study of Human Health. “Once we have isolated the active ingredients, we plan to further test for their safety and for their long-range potential as medicines against COVID-19.”

    Quave is an ethnobotanist, studying how traditional people have used plants for medicine to identify promising new candidates for modern-day drugs. Her lab curates the Quave Natural Product Library, which contains thousands of botanical and fungal natural products extracted from plants collected at sites around the world.

    Caitlin Risener, a PhD candidate in Emory’s Molecular and Systems Pharmacology graduate program and the Center for the Study of Human Health, is first author of the current paper.

    In previous research to identify potential molecules for the treatment of drug-resistant bacterial infections, the Quave lab focused on plants that traditional people had used to treat skin inflammation.

    Given that COVID-19 is a newly emerged disease, the researchers took a broader approach. They devised a method to rapidly test more than 1,800 extracts and 18 compounds from the Quave Natural Product Library for activity against SARS-CoV-2.

    “We’ve shown that our natural products library is a powerful tool to help search for potential therapeutics for an emerging disease,” Risener says. “Other researchers can adapt our screening method to search for other novel compounds within plants and fungi that may lead to new drugs to treat a range of pathogens.”

    SARS-CoV-2 is an RNA virus with a spike protein that can bind to a protein called ACE2 on host cells. “The viral spike protein uses the ACE2 protein almost like a key going into a lock, enabling the virus to break into a cell and infect it,” Quave explains.

    The researchers devised experiments with virus-like particles, or VLPs, of SARS-CoV-2, and cells programmed to overexpress ACE2 on their surface. The VLPs were stripped of the genetic information needed to cause a COVID-19 infection. Instead, if a VLP managed to bind to an ACE2 protein and enter a cell, it was programmed to hijack the cell’s machinery to activate a fluorescent green protein.

    A plant extract was added to the cells in a petri dish before introducing the viral particles. By shining a fluorescent light on the dish, they could quickly determine whether the viral particles had managed to enter the cells and activate the green protein.   

    The researchers identified a handful of hits for extracts that protected against viral entry and then homed in on the ones showing the strongest activity: Tall goldenrod and eagle fern. Both plant species are native to North America and are known for traditional medicinal uses by Native Americans.

    Additional experiments showed that the protective power of the plant extracts worked across four variants of SARS-CoV-2: Alpha, theta, delta and gamma.

    To further test these results, the Quave lab collaborated with co-author Raymond Schinazi, Emory professor of pediatrics, director of Emory’s Division of Laboratory of Biochemical Pharmacology and co-director of the HIV Cure Scientific Working Group within the NIH-sponsored Emory University Center for AIDS Research. A world leader in antiviral development, Schinazi is best known for his pioneering work on breakthrough HIV drugs.

    The higher biosecurity rating of the Schinazi lab enabled the researchers to test the two plant extracts in experiments using infectious SARS-CoV-2 virus instead of VLPs. The results confirmed the ability of the tall goldenrod and eagle fern extracts to inhibit the ability of SARS-CoV-2 to bind to a living cell and infect it.

    “Our results set the stage for the future use of natural product libraries to find new tools or therapies against infectious diseases,” Quave says.

    As a next step, the researchers are working to determine the exact mechanism that enables the two plant extracts to block binding to ACE2 proteins.

    For Risener, one of the best parts about the project is that she collected samples of tall goldenrod and eagle fern herself. In addition to gathering medicinal plants from around the globe, the Quave lab also makes field trips to the forests of the Joseph W. Jones Research Center in South Georgia. The Woodruff Foundation established the center to help conserve one of the last remnants of the unique longleaf pine ecosystem that once dominated the southeastern United States.

    “It’s awesome to go into nature to identify and dig up plants,” Risener says. “That’s something that few graduate students in pharmacology get to do. I’ll be covered in dirt from head to toe, kneeling on the ground and beaming with excitement and happiness.”

    She also assists in preparing the plant extracts and mounting the specimens for the Emory Herbarium.

    “When you collect a specimen yourself, and dry and preserve the samples, you get a personal connection,” she says. “It’s different from someone just handing you a vial of plant material in a lab and saying, ‘Analyze this.’”

    After graduating, Risener hopes for a career in outreach and education for science policy surrounding research into natural compounds. A few of the more famous medicines derived from botanicals include aspirin (from the willow tree), penicillin (from fungi) and the cancer therapy Taxol (from the yew tree).

    “Plants have such chemical complexity that humans probably couldn’t dream up all the botanical compounds that are waiting to be discovered,” Risener says. “The vast medicinal potential of plants highlights the importance of preserving ecosystems.”

    Co-authors of the current paper include: Sumin Woo, Tharanga Samarakoon, Marco Caputo and Emily Edwards (the Quave lab and Emory’s Center for the Study of Human Health); Keivan Zandi, Shu Ling Goh and Jessica Downs-Bowen (the Schinazi lab); Kier Klepzig (Joseph W. Jones Research Center); and Wendy Applequist (Missouri Botanical Garden).

    Funding for the paper was provided by the Marcus Foundation, the NIH-funded Center for AIDS Research and the NIH National Center for Complementary and Integrative Health.

    [ad_2]

    Emory University

    Source link

  • ‘Natural killer’ immune cells can modify tissue inflammation: study

    ‘Natural killer’ immune cells can modify tissue inflammation: study

    [ad_1]

    Newswise — Melbourne researchers have improved our understanding of how the immune system is regulated to prevent disease, identifying a previously unknown role of ‘natural killer’ (NK) immune cells. 

    The Monash University-led study identified a new group of immune cells, known as tissue-resident memory natural killer (NKRM) cells. NKRM cells limited immune responses in tissues and prevented autoimmunity, which is when the immune system makes a mistake and attacks the body’s own tissues or organs.

    While additional research is required, the discovery may ultimately be used to treat autoimmune diseases like Sjogren’s Syndrome and possibly chronic inflammatory conditions.

    Published in Immunity, the preclinical research is led by senior author Professor Mariapia Degli-Esposti  and first author Dr Iona Schuster from the Monash Biomedicine Discovery Institute (BDI), in close ongoing collaboration with the Lions Eye Institute.

    Originally, NK cells were thought to be short lived cells that circulate in the blood with the sole function of identifying and quickly killing virally infected or damaged cells.

    The team’s previous research established that NK cells’ role is far more complex, and the latest study demonstrates for the first time that a subset of NK cells, NKRM, are critical in regulating immune responses in tissues.

    “This is key to preserving tissue function and preventing autoimmunity from developing,” Dr Schuster said. “While long-lived tissue resident memory T cells (TRM) have been described, the primary known function of these cells is to protect the host against reinfection.

    “Our discovery of tissue-resident memory natural killer (NKRM) cells establishes that the function of some memory cells that live in tissues is to protect from excessive inflammation rather than protect against recurring infection.”

    Professor Degli-Esposti, BDI Head of Experimental and Viral Immunology, said the findings significantly improved our fundamental understanding of how the immune system is regulated to prevent disease. 

    “One of the main obstacles in cancer immunotherapy … is the development of immune related adverse events, which include the development or flare-up of autoimmune complications,” she said.
    “These events are due to ‘super’ or ‘uncontrolled’ activation of the immune system as a result of the brakes being removed by the therapeutic strategy.

    “Furthermore, many therapies cause collateral damage to tissues where tumours are localised. Thus, NKRM may be an adjunct or follow-up therapy to restore immune balance and bring back tissue health.”

    Read the full paper in Immunity: Infection induces tissue resident memory NK cells that safeguard tissue healthhttps://www.cell.com/immunity/fulltext/S1074-7613(23)00026-2

    Key findings

    1. Following infection with a common virus, cytomegalovirus, ‘natural killer’ (NK) cells were recruited from the circulation into inflamed tissues where they were retained and developed into a long-lived population of cells that researchers called tissue-resident memory natural killer (NKRM) cells.
    2.  Unlike NK cells, NKRM did not participate in virus control.
    3. In the absence of NKRM, infection led to tissue damage and the development of autoimmunity which presented as Sjogren’s Syndrome, one of the most common autoimmune diseases.
    Therefore, researchers identified a new population of cells that specifically localise to tissues to modulate immune responses to prevent immune pathology and autoimmunity.

    About the immune system

    Dysregulated immune or inflammatory processes contribute to many diseases. While the immune system protects against infection, a dysregulated immune response can lead to chronic inflammation, and in some instances cause tissue damage. Viral infections can trigger these processes, as the Covid pandemic has highlighted.

    About autoimmune diseases

    Autoimmune diseases arise when immune responses are misdirected and the immune system attacks host tissues and organs. Appropriate regulation of immune responses is therefore critical. As an example, Sjogren’s Syndrome is one of the most common autoimmune diseases and severely affects vision as patients are not able to produce tears. In most cases this leads to severe discomfort, but complications can lead to corneal damage and compromise vision. There is no cure for Sjogren’s Syndrome or its ocular complications.

    About the Monash Biomedicine Discovery Institute
    Committed to making the discoveries that will relieve the future burden of disease, the Monash Biomedicine Discovery Institute (BDI) at Monash University brings together more than 120 internationally-renowned research teams. Spanning seven discovery programs across Cancer, Cardiovascular Disease, Development and Stem Cells, Infection, Immunity, Metabolism, Diabetes and Obesity, and Neuroscience, Monash BDI is one of the largest biomedical research institutes in Australia. Our researchers are supported by world-class technology and infrastructure, and partner with industry, clinicians and researchers internationally to enhance lives through discovery.

    About the Lions Eye Institute
    At the Lions Eye Institute, we make a difference to people’s lives through excellent patient care and by pushing the frontiers of science to discover new treatments and cures for eye disease. As a not for profit organisation, the Lions Eye Institute spans the dual complementary pathways of research and clinical care. We bring together a globally recognised team of researchers and clinicians who continually build on each other’s discoveries, knowledge and expertise to deliver sight-saving treatment and care around the world. The quest for knowledge and its life-changing applications for patients is what drives our work.
    For more Lions Eye Institute media stories, visit our news site.

    For more Monash media stories, visit our news and events site

    [ad_2]

    Monash University

    Source link

  • Mosquito’s DNA could provide clues on gene expression, regulation

    Mosquito’s DNA could provide clues on gene expression, regulation

    [ad_1]

    Newswise — HOUSTON – (Feb. 9, 2023) – When it comes to DNA, one pesky mosquito turns out to be a rebel among species.

    Researchers at Rice University’s Center for Theoretical Biological Physics (CTBP) are among the pioneers of a new approach to studying DNA. Instead of focusing on chromosomes as linear sequences of genetic code, they’re looking for clues on how their folded 3D shapes might determine gene expression and regulation.

    For most living things, their threadlike chromosomes fold to fit inside the nuclei of cells in one of two ways. But the chromosomes of the Aedes aegypti mosquito — which is responsible for the transmission of tropical diseases such as denguechikungunyazikamayaro and yellow fever — defy this dichotomy, taking researchers at the CTBP by surprise.

    The Aedes aegypti’s chromosomes organize as fluid-yet-oriented “liquid crystals,” different from all other species, according to their study published in Nature Communications.

    “Understanding DNA is a key to understanding how life works,” said Rice theoretical physicist Peter Wolynes, a co-author on the study. “We are only just beginning to learn how the 3D architecture of chromosomes influences the functioning of genomes.”

    A 2021 collaborative study co-led by a team from the CTBP and published in Science reported that chromosomes display one of two structural patterns when cells are not dividing, the stage in the cell life cycle known as interphase.

    “In a ‘type two’ genome architecture — like that found in humans and chickens, for instance — chromosomes form territories and don’t mix together that much,” said Vinícius Contessoto, a CTBP research scientist who is a lead co-author on the latest study and was also a co-author on the 2021 study.

    The still-unknown forces that keep active and inactive parts of “type two” chromosomes separate from each other during interphase behave like those that prevent oil and water from mixing together.

    “In a ‘type one’ architecture, like that found in yeast or in many plants, the regions of the chromosomes known as centromeres come together, folding them into an intermeshed, hairpin-like structure, polarized with telomeres ” said José Onuchic, Rice’s Harry C. and Olga K. Wiess Professor of Physics and Astronomy, and a professor of chemistry and biosciences.

    “Something that’s surprising to me is that even though so many different species have been mapped, they still largely fall into one of these two different classes,” Wolynes said. “The Aedes aegypti mosquito is the first real outlier.”

    The genome of the Aedes aegypti is roughly half the length of the human genome and is organized into six large chromosomes, as opposed to humans’ 46. “We used to think that the chromosomes of the mosquito did not form territories, but in fact they do form these elongated territories,” Contessoto said.

    “During interphase, ‘type two’ chromosomes are really very fluid, disordered things balled up into droplet-shaped territories,” said Wolynes, Rice’s Bullard-Welch Foundation Professor of Science and a professor of chemistry, of biochemistry and cell biology, of physics and astronomy, and of materials science and nanoengineering and co-director of the CTBP.

    The chromosomes of the Aedes aegypti mosquito display fluid characteristics, separating from one another like liquid droplets of oil and water. At the same time, they are partially condensed by compaction forces, which gives them an unusual shape, oriented like an overlong football, suggesting their consistency is also similar to that of a crystal.

    Moreover, if force is applied to a regular “type two” nucleus and it is deformed, the organization of the chromosomes inside remains unaffected. “It’s like poking a water balloon — it reverts to its prior shape. But when we poke the nucleus of the mosquito cells, the chromosomes’ patterns inside change dramatically,” said Onuchic.

    “This is an intriguing feature of ‘type one’ chromosome architecture that suggests there is a possible mechanism linking gene regulation to mechanical inputs on the cell,” said Onuchic. In 2020, he and collaborators confirmed the existence of a mechanism connecting genome structure to gene expression.

    Other co-authors of the new study are Erez Lieberman Aiden, a Rice adjunct assistant professor of computer science and an assistant professor of computational and applied mathematics, an associate professor of molecular and human genetics and a principal investigator in the joint Rice/Baylor College of Medicine Center for Genome Architecture; Olga Dudchenko, an assistant professor in the Center for Genome Architecture and former CTBP postdoctoral fellow; and Michele Di Pierro, an assistant professor of physics at Northeastern University. All are CTBP members.

    The research was supported by the National Science Foundation (2019745, 2210291, 2019276, 2021795); the Welch Foundation (C-1792, Q-1866); the Cancer Prevention and Research Institute of Texas; the São Paulo State Research Foundation and Higher Education Personnel, and Higher Education Personnel Improvement Coordination (2016/13998-8, 2017/09662-7); the D.R. Bullard-Welch Chair at Rice (C-0016); the McNair Medical Institute Scholar Award; the National Institutes of Health (UM1HG009375, RM1HG011016-01A1, R35GM146852); and the AMD HPC Fund.

    -30-

    This release can be found online at news.rice.edu.

    Follow Rice News and Media Relations via Twitter @RiceUNews.

    Peer-reviewed paper:

    Interphase chromosomes of the Aedes aegypti mosquito are liquid crystalline and can sense mechanical cues | Nature Communications | DOI: 10.1038/s41467-023-35909-2

    https://doi.org/10.1038/s41467-023-35909-2

    Authors: Vinícius Contessoto, Olga Dudchenko, Erez Lieberman Aiden, Peter Wolynes, José Onuchic and Michele Di Pierro

    Image downloads:

    https://news-network.rice.edu/news/files/2023/02/CTBP_NatureCommunications_image1_LG.jpg

    CAPTION: 3D simulation of the genome structure of the Aedes aegypti mosquito. The elongated territories formed by each of the six chromosomes are color-coded and shown separately (bottom) and together as part of the whole genome (top). (Image adapted from Nature Communications, https://doi.org/10.1038/s41467-023-35909-2, under a Creative Commons Attribution 4.0 International License.)

    https://news-network.rice.edu/news/files/2023/02/CTBP_NatureCommunications_image2_LG.jpg
    CAPTION: The image shows the effects of applying tension to cell nuclei on contacts between the chromosomes of both the human and mosquito genomes (red and white squares), with corresponding 3D simulations (colorful stringlike structures). The human interphase chromosome is less sensitive to mechanical cues than the mosquito interphase chromosome. (Image adapted from Nature Communications, https://doi.org/10.1038/s41467-023-35909-2, under a Creative Commons Attribution 4.0 International License.)

    https://news-network.rice.edu/news/files/2023/02/230203_Vinicius-Contessoto_LG.jpg
    CAPTION: Vinícius Contessoto is a researcher in the Center for Biological Theoretical Physics at Rice University. (Photo by Gustavo Raskosky/Rice University)

    https://news-network.rice.edu/news/files/2023/02/230203_Onuchic_LG.jpg
    CAPTION: José Onuchic is the Harry C. and Olga K. Wiess Chair of Physics and professor of chemistry and biosciences at Rice University. (Photo by Gustavo Raskosky/Rice University)

    https://news-network.rice.edu/news/files/2023/02/230203_ContessotoOnuchic_LG.jpg
    CAPTION: Vinícius Contessoto (left) and José Onuchic are lead co-authors on the study published last month in Nature Communications. (Photo by Gustavo Raskosky/Rice University)

    Related stories:

    NSF extends Physics of Living Systems network at Rice:
    https://news2.rice.edu/2021/09/27/nsf-extends-physics-of-living-systems-network-at-rice/

    Biologists construct a ‘periodic table’ for cell nuclei:
    https://news.rice.edu/news/2021/biologists-construct-periodic-table-cell-nuclei

    At our cores, we’re all strengthened by ‘dumbbells’:
    https://news.rice.edu/news/2020/our-cores-were-all-strengthened-dumbbells

    Snake-like proteins can wrangle DNA:
    https://news.rice.edu/news/2020/snake-proteins-can-wrangle-dna

    Ring-shaped protein complex wrangles DNA:
    https://news2.rice.edu/2018/11/02/ring-shaped-protein-complex-wrangles-dna/

    Links:

    BioScience Research Collaborative: https://brc.rice.edu/

    Center for Theoretical Biological Physics: https://ctbp.rice.edu/

    Department of Chemical and Biomolecular Engineering: https://chbe.rice.edu/

    Department of Chemistry: https://chemistry.rice.edu/

    Department of Physics and Astronomy: https://physics.rice.edu/

    George R. Brown School of Engineering: https://engineering.rice.edu

    Ken Kennedy Institute: https://kenkennedy.rice.edu/

    Wiess School of Natural Sciences: https://naturalsciences.rice.edu

    Wolynes Research Lab: https://wolynes.rice.edu/

    Located on a 300-acre forested campus in Houston, Rice University is consistently ranked among the nation’s top 20 universities by U.S. News & World Report. Rice has highly respected schools of Architecture, Business, Continuing Studies, Engineering, Humanities, Music, Natural Sciences and Social Sciences and is home to the Baker Institute for Public Policy. With 4,552 undergraduates and 3,998 graduate students, Rice’s undergraduate student-to-faculty ratio is just under 6-to-1. Its residential college system builds close-knit communities and lifelong friendships, just one reason why Rice is ranked No. 1 for lots of race/class interaction and No. 1 for quality of life by the Princeton Review. Rice is also rated as a best value among private universities by Kiplinger’s Personal Finance.

    [ad_2]

    Rice University

    Source link

  • Scientists discover receptor that blocks COVID-19 infection

    Scientists discover receptor that blocks COVID-19 infection

    [ad_1]

    Newswise — University of Sydney scientists have discovered a protein in the lung that blocks SARS-CoV-2 infection and forms a natural protective barrier in the human body.

    This protein, the leucine-rich repeat-containing protein 15 (LRRC15), is an inbuilt receptor that binds the SARS-CoV-2 virus without passing on the infection.

    The research opens up an entirely new area of immunology research around LRRC15 and offers a promising pathway to develop new drugs to prevent viral infection from coronaviruses like COVID-19 or deal with fibrosis in the lungs.

    The study has been published in the journal PLOS Biology. It was led by Professor Greg Neely with his team members Dr Lipin Loo, a postdoctoral researcher, and PhD student Matthew Waller at the Charles Perkins Centre and the School of Life and Environmental Sciences.

    The University study is one of three independent papers that reveal this specific protein’s interaction with COVID-19.

    “Alongside two other groups, one at Oxford, the other at Brown and Yale in the USA, we found a new receptor in the LRRC15 protein that can stop SARS-CoV-2. We found that this new receptor acts by binding to the virus and sequestering it which reduces infection,” Professor Neely said. 

    “For me, as an immunologist, the fact that there’s this natural immune receptor that we didn’t know about, that’s lining our lungs and blocks and controls virus, that’s crazy interesting.

    “We can now use this new receptor to design broad acting drugs that can block viral infection or even suppress lung fibrosis.”

    What is LRRC15?

    The COVID-19 virus infects humans by using a spike protein to attach to a specific receptor in our cells. It primarily uses a protein called the angiotensin-converting enzyme 2 (ACE2) receptor to enter human cells. Lung cells have high levels of ACE2 receptors, which is why the COVID-19 virus often causes severe problems in this organ of infected people.

    Like ACE2, LRRC15 is a receptor for coronavirus, meaning the virus can bind to it. But unlike ACE2, LRRC15 does not support infection. It can, however, stick to the virus and immobilise it. In the process, it prevents other vulnerable cells from becoming infected.

    “We think it acts a bit like Velcro, molecular Velcro, in that it sticks to the spike of the virus and then pulls it away from the target cell types,” Dr Loo said.

    “Basically, the virus is coated in the other part of the Velcro, and while it’s trying to get to the main receptor, it can get caught up in this mesh of LRRC15,” Mr Waller said. 

    LRRC15 is present in many locations such as lungs, skin, tongue, fibroblasts, placenta and lymph nodes. But the researchers found human lungs light up with LRRC15 after infection.   

    “When we stain the lungs of healthy tissue, we don’t see much of LRRC15, but then in COVID-19 lungs, we see much more of the protein,” Dr Loo said.

    “We think this newly identified protein could be part of our body’s natural response to combating the infection creating a barrier that physically separates the virus from our lung cells most sensitive to COVID-19.”

    Implications of the research

    “When we studied how this new receptor works, we found that this receptor also controls antiviral responses, as well as fibrosis, and could link COVID-19 infection with lung fibrosis that occurs during long COVID,” Mr Waller said.

    “Since this receptor can block COVID-19 infection, and at the same time activate our body’s anti-virus response, and suppress our body’s fibrosis response, this is a really important new gene,” Professor Neely said.

    “This finding can help us develop new antiviral and antifibrotic medicines to help treat pathogenic coronaviruses, and possibly other viruses or other situations where lung fibrosis occurs.

    “For fibrosis, there are no good drugs: for example, idiopathic pulmonary fibrosis is currently untreatable.”

    Fibrosis is a condition in which lung tissue becomes scarred and thickened, causing breathing difficulties. COVID-19 can cause inflammation and damage to the lungs, leading to fibrosis.

    The authors said they are developing two strategies against COVID-19 using LRRC15 that could work across multiple variants – one which targets the nose as a preventative treatment, and another aimed at the lungs for serious cases.

    The researchers also said that the presence or lack of LRRC15, which is involved in lung repair, is an important indication of how severe a COVID-19 infection might become.

    “A group at Imperial College London independently found that absence of LRRC15 in the blood is associated with more severe COVID, which supports what we think is happening.” Dr Loo said. “If you have less of this protein, you likely have serious COVID. If you have more of it, your COVID is less severe.

    “We are now trying to understand exactly why this is the case.”

    The research involved screening human cell cultures for genes and investigating the lungs of human COVID-19 patients.

    [ad_2]

    University of Sydney

    Source link

  • Microbiome disturbances reported as signature of chronic fatigue syndrome/myalgic encephalomyelitis

    Microbiome disturbances reported as signature of chronic fatigue syndrome/myalgic encephalomyelitis

    [ad_1]

    Newswise — New research reveals differences in the gut microbiomes of people with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) compared to those of healthy controls.

    ME/CFS is characterized by unexplained debilitating fatigue, cognitive dysfunction, gastrointestinal disturbances, among other symptoms.

    The study was led by scientists at the Center for Infection and Immunity (CII) at Columbia University Mailman School of Public Health, as part of the Center for Solutions for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, an inter-disciplinary, inter-institutional research group dedicated to understanding the biology of the disease in order to develop effective means to diagnose, treat and prevent it. Findings appear in the journal Cell Host & Microbe.

    The researchers conducted metagenomic and metabolomic analyses of fecal samples collected from geographically diverse cohort of 106 cases and 91 healthy controls. Results revealed differences in gut microbiome diversity, abundances, functional biological pathways, and interactions between bacteria. Cases and controls were matched for age, sex, geography, and socioeconomic status.

    Gut bacteria Faecalibacterium prausnitzii and Eubacterium rectale, which are both normally abundant and health-promoting, were reduced in ME/CFS participants. For both bacteria, researchers also found a deficient microbial capacity for synthesizing butyrate, the main fuel for the body’s colon cell, with ME/CFS. The abundance of Faecalibacterium prausnitzii was inversely associated with fatigue severity.

    The only other species identified with reduced relative abundance in ME/CFS was C. secundus, an acetate-producer, that could contribute to the net acetate deficiency the researchers found in ME/CFS subjects. Acetate is used by butyrate-producing bacteria to produce butyrate.

    An additional nine species had increased relative abundance in ME/CFS compared to healthy controls, including C. bolteae which in other research has correlated with fatigue in multiple sclerosis. Another, R. gnavus, has been associated with inflammatory bowel disease.

    “The gut microbiome is a complex ecological community teeming with diverse inter-species interactions that can be beneficial or harmful. Our research finds that in people with ME/CFS, there can be extensive rewiring of the networks of bacteria in this system,” says study senior author Brent Williams, PhD, assistant professor of epidemiology in CII at Columbia Mailman School of Public Health.

    “Understanding the connection between ME/CFS and disturbances in the gut microbiome may lead to ways to classify the disease and targets for therapeutic trials,” adds co-author W. Ian Lipkin, MD, CII director and John Snow Professor of Epidemiology at Columbia Mailman School.

    The study’s first author is Cheng Guo, PhD, senior programmer analyst at CII. Additional co-authors are listed in the publication.

    The research was funded by the National Institutes of Health grant to the Center for Solutions for ME/CFS at Columbia University (grant number 1U54AI138370), NIH grant R56AI120724, and anonymous donors through the Crowdfunding Microbe Discovery Project.

    The authors declare no competing interests.

    About ME/CFS

    Experts estimate there are between 800,000 and 2 million Americans with ME/CFS, a complex, debilitating disorder characterized by extreme fatigue after exertion and other symptoms including muscle and joint pain, cognitive dysfunction, sleep disturbance, and orthostatic intolerance. Currently, there is no diagnostic test for the disease; instead, patients are diagnosed based on a clinical examination and history and an exclusion of other disorders.

    Prior Research on ME/CFS

    In a 2017 study, CII scientists reported discovered abnormal levels of specific gut bacteria related to ME/CFS in patients with and without concurrent irritable bowel syndrome, IBS. A year later, another study identified a constellation of metabolites related to ME/CFS, providing the ability to predict whether or not someone has the disorder with a confidence of 84 percent.

    In a 2015 study, CII researchers identified distinct immune changes in patients diagnosed with ME/CFS. These immune signatures represented the first robust physical evidence that ME/CFS is a biological illness as opposed to a psychological disorder, and the first evidence that the disease has distinct stages. In a 2012 study, researchers ruled out a purported link between a mouse retrovirus called XMRV and ME/CFS.

    [ad_2]

    Columbia University, Mailman School of Public Health

    Source link

  • Protein droplets may cause many types of genetic disease

    Protein droplets may cause many types of genetic disease

    [ad_1]

    Newswise — Most proteins localize to distinct protein-rich droplets in cells, also known as “cellular condensates”. Such proteins contain sequence features that function as address labels, telling the protein which condensate to move into. When the labels get screwed up, proteins may end up in the wrong condensate. According to an international team of researchers from clinical medicine and basic biology, this could be the cause of many unresolved diseases. The findings appeared in the journal Nature.

    Patients with BPTA syndrome have characteristically malformed limbs featuring short fingers and additional toes, missing tibia bones in their legs and reduced brain size. As the researchers found out, BPTAS is caused by a special genetic change that causes an essential protein to migrate to the nucleolus, a large proteinaceous droplet in the cell nucleus. As a result, the function of the nucleolar condensate is inhibited and developmental disease develops.

    “What we discovered in this one disease might apply to many more disorders. It is likely not a rare unicorn that exists only once. We just could not see the phenomenon until now because we did not know how to look for it,” says Denise Horn, a clinical geneticist at the Institute of Medical and Human Genetics at Charité – Universitätsmedizin Berlin.

    In collaboration with scientists at the Max Planck Institute for Molecular Genetics (MPIMG) in Berlin, the University Hospital Schleswig-Holstein (UKSH), and contributors from all around the world, the team is pushing open a door to new diagnoses that could lead to the elucidation of numerous other diseases as well as possible future therapies.

    “We discovered a new mechanism that could be at play in a wide range of diseases, including hereditary diseases and cancer,” says Denes Hnisz, Research Group Leader at the MPIMG. “In fact, we have discovered over 600 similar mutations, 101 of which are known to be associated with different disorders.”

    “The actual work is just starting now,” adds human geneticist Malte Spielmann of UKSH in Lübeck and Kiel. “We will find many more genes with such disease-causing mutations and can now test their mode of action.”

    An unusual mutation

    Affected individuals have complex and striking malformations of the limbs, face, and nervous and bone systems, only partially described by the already-long disease name “brachyphalangy-polydactyly-tibial aplasia/hypoplasia syndrome” (BPTAS).

    “With fewer than ten documented cases worldwide, the disease is not only rare, but ultra-rare,” says Martin Mensah, clinical geneticist at the Institute of Medical and Human Genetics at Charité. To track down the cause, he and his colleagues decoded the genome of five affected individuals and found that the gene for the protein HMGB1 was altered in all patients.

    This protein has the task of organizing the genetic material in the cell nucleus and facilitates the interaction of other molecules with the DNA, for example to read genes.

    In mice, a complete loss of the gene on both chromosomes is catastrophic and leads to death of the embryo. In some patients with only one copy mutated, however, the cells are using the intact copy on the other chromosome, resulting only in mild neurodevelopmental delay. But the newly discovered cases did not fit this scheme.

    “All five unrelated individuals featured the same ultra-rare disorder and had virtually the same mutation”, says Mensah, who is a fellow of the Clinician Scientist Program operated by the Berlin Institute of Health at Charité (BIH) and Charité. “This is why we are sure that the HMGB1 mutation is the cause of the disease. However, at that point, we had no clue how the gene product functionally caused disease, especially given that loss-of-function mutations were reported to result in other phenotypes.”

    Charged protein extensions

    A closer look revealed that different mutations of HMGB1 have different consequences. The sequencing data showed that in the affected individuals with the severe malformations, the reading frame for the final third of the HMGB1 gene is shifted.

    After translation to protein, the corresponding region is now no longer equipped with negative but with positively charged amino acid building blocks. This can happen if a number of genetic letters not divisible by three is missing in the sequence, because exactly three consecutive letters always code for one building block of the protein.

    However, the tail part of the protein does not have a defined structure. Instead, this section hangs out of the molecule like a loose rubber band. The purposes of such protein tails (also called “intrinsically disordered regions”) are difficult to study because they often become effective only in conjunction with other molecules. So how might their mutation lead to the observed disease?

    Protein droplets in the cell

    To answer this question, the medical researchers approached biochemists Denes Hnisz and Henri Niskanen at the MPIMG, who work with cellular condensates that control important genes. These droplet-like structures behave much like the oil and vinegar droplets in a salad dressing. Composed of a large number of different molecules, they are separated from their surroundings and can undergo dynamic changes.

    “We think condensates are formed in the cell for practical reasons,” Niskanen explains. Molecules for a specific task are grouped together in this way, say to read a gene. For this task alone, he says, several hundred proteins need to somehow make their way to the right place.

    “Intrinsically disordered regions, which tend not to have an obvious biochemical role, are thought to be responsible for forming condensates,” Niskanen says, giving an example to describe how important the physical properties of the protein extensions are in this regard. “I can easily make a ball from many loose rubber bands that holds together relatively tightly and that can be taken apart with little effort. A ball of smooth fishing line or sticky tape, on the other hand, would behave quite differently.”

    Solidifying droplets

    The nucleolus within the cell nucleus is also a condensate, which appears as a diffuse dark speck under the microscope. This is where many proteins with positively charged tails like to linger. Many of these provide the machinery required for protein synthesis, making this condensate essential for cellular functions.

    The mutant protein HMGB1 with its positively charged molecular tail is attracted to the nucleolus as well, as the team observed from experiments with isolated protein and with cell cultures.

    But since the mutated protein region has also gained an oily, sticky part, it tends to clump. The nucleolus loses its fluid-like properties and increasingly solidifies, which Niskanen was able to observe under the microscope. This impaired the vital functions of the cells – with the mutated protein, more cells in a culture died compared to a culture of cells without the mutation.

    Combing through databases

    The research team then searched databases of genomic data from thousands of individuals looking for similar incidents. In fact, the scientists were able to identify more than six hundred similar mutations in 66 proteins, in which the reading frame had been shifted by a mutation in the protein tail, making it both more positively charged and more “greasy”. Of the mutations, 101 had previously been linked to several different disorders.

    For a cell culture assay, the team selected 13 mutant genes. In 12 out of 13 cases, the mutant proteins had a preference to localize into the nucleolus. About half of the tested proteins impaired the function of the nucleolus, resembling the disease mechanism of BPTA syndrome.

    New explanations for existing diseases

    “For clinical research, our study could have an eye-opening effect,” says Malte Spielmann, who led the research together with Denes Hnisz and Denise Horn. “In the future, we can certainly elucidate the causes of some genetic diseases and hopefully one day treat them.”

    However, “congenital genetic diseases such as BPTAS are almost impossible to cure even with our new knowledge”, says Horn. “Because the malformations already develop in the womb, they would have to be treated with drugs before they develop. This would be very difficult to do.”

    But tumor diseases are also predominantly genetically determined, adds Hnisz: “Cellular condensates and the associated phase separation are a fundamental mechanism of the cell that also plays a role in cancer. The chances of developing targeted therapies for this are much better.”

    [ad_2]

    Max Planck Society (Max-Planck-Gesellschaft)

    Source link

  • How a high fat diet allows expulsion of intestinal parasite worms

    How a high fat diet allows expulsion of intestinal parasite worms

    [ad_1]

    Newswise — Scientists have discovered that a high-fat diet allows the immune system to eliminate a parasitic worm which is a major cause of death and illness in the developing world.

    Parasitic worms affect up to a billion people, particularly in developing nations with poor sanitation. One of these parasites known as “whipworm” can cause long lasting infections in the large intestine.

    Researchers from Lancaster University and the University of Manchester  in the UK have discovered that a high-fat diet allows the immune system to eliminate the parasite. 

    Lead author Dr Evelyn Funjika, formerly at Manchester and now at the University of Zambia, said: “Just like the UK, the cheapest diets are often high in fat and at-risk communities to whipworm are increasingly utilising these cheap diets. Therefore, how worm infection and western diets interact is a key unknown for developing nations.

    “In order to be able to study how nutrition affects parasite worm infection, we have been using a mouse model, Trichuris muris, closely related to the human whipworm Trichuris trichiura and seeing how a high-fat diet impacts immunity.”

    It has been previously shown that immune responses which expel the parasite rely on white blood cells called T-helper 2 cells, specialised for eliminating gastrointestinal parasites.

    The findings, published in the journal “Mucosal Immunology”, demonstrate how a high-fat diet, rather than obesity itself, increases a molecule on T-helper cells called ST2 and this allows an increased T-helper 2 response which expels the parasite from the large intestinal lining.  

    Dr John Worthington from the Department of Biomedical and Life Science at Lancaster University co-led the research.

    “We were quite surprised by what we found during this study. High-fat diets are mostly associated with increased pathology during disease. However, in the case of whipworm infection this high fat diet licenses the T-helper cells to make the correct immune response to expel the worm.”

    Co-lead Professor Richard Grencis from the University of Manchester said: “Our studies in mice on a standard diet demonstrate that ST2 is not normally triggered when expelling the parasite, but the high-fat diet boosts the levels of ST2 and hence allows expulsion via an alternative pathway”.

    Co-lead Professor David Thornton from the University of Manchester added: “It was really fascinating that simply altering the diet completely switched the immune response in the gut from one that fails to expel the parasite, to one that brings about all the correct mechanisms to eliminate it.”

    However, Dr Worthington added caution to the findings.

    “Before you order that extra take-away, we have previously published that weight loss can aid the expulsion of a different gut parasite worm. So these results may be context specific, but what is really exciting is the demonstration of how diet can profoundly alter the capacity to generate protective immunity and this may give us new clues for treatments for the millions who suffer from intestinal parasitic infections worldwide.”

    The research was funded by the Commonwealth Scholarship Commission, The Wellcome Trust and EPSRC (Engineering and Physical Sciences Research Council).

    [ad_2]

    Lancaster University

    Source link

  • Researchers use Artificial Intelligence to personalise cancer patient treatments

    Researchers use Artificial Intelligence to personalise cancer patient treatments

    [ad_1]

    Newswise — Researchers at the University of Sussex are using Artificial Intelligence (AI) technology to analyse different types of cancer cells to understand different gene dependencies, and to identify genes that are critical to a cell’s survival. Sussex researchers have done this by developing a prediction algorithm that works out which genes are essential in the cell, by analysing the genetic changes in the tumour. This can be used to identify actionable targets that in time could guide oncologists to personalise cancer patient treatments

    Dr Frances Pearl, Senior Lecturer in Bioinformatics in the School of Life Sciences at the University of Sussex says

    “Our vision is to take advantage of the decreasing cost of DNA sequencing and to harness the power of AI to understand cancer cell differences and what they mean for the individual patient’s treatment. Through our research, we were able to identify cell-specific gene dependencies using only the DNA sequence and RNA levels in that cell, which are easily and cheaply obtainable from tumour biopsy samples.

    “This is an incredibly exciting step in our research which means that we can now work to improve the technology so that it can be offered to oncologists and help in the treatment pathways for their patients.”

    Cancer treatments are primarily prescribed on the basis of the location and type of cancer. Genetic differences in tumours can make standard cancer treatments ineffective. Using a personalised approach to guide treatment could improve life expectancy, quality of life and reduce unnecessary side effects of cancer patients.

    In each cell,  there are around 20,000 genes that contain the information needed to make proteins. Around 1,000 of those genes are essential, meaning they are required for the cell to survive. When normal cells become cancer cells, oncogenes (that is, those genes with the potential to cause cancer) become activated and tumour suppressor genes become inactivated, causing a rewiring of the cell. This causes the cell to become dependent on a new set of genes to survive, and this can then be exploited to kill the cancer cells.

    By using this new technology to target protein products of tumour-specific dependent genes, cancer cells can be killed, leaving the normal cells which are not dependent on these genes relatively unharmed. Although dependencies can be determined using intensive laboratory techniques, it is costly and time consuming and would not be feasible to analyse all tumour samples in this way.

    – End –

    [ad_2]

    University of Sussex

    Source link

  • Establishing cell lines to improve iPSC research

    Establishing cell lines to improve iPSC research

    [ad_1]

    Newswise — Farmington, CT– iPSC lines have become essential for determining the underlying genetic drivers of human disease. Genomes of iPSCs can be easily edited using the bacteria-based CRISPR/Cas9 technology to introduce or correct disease-associated variants. 

    By focusing on one gene variation at a time, results of experiments have a clear genetic cause and effect to be easily compared to previous data. What poses a challenge for accurate disease modeling is the inherent variation between iPSC lines, as well as the wide variety of cell lines used in research between institutions, creating unwanted obstacles in data interpretation.

    Jackson Laboratory (JAX) Professor of Cellular Engineering Bill Skarnes, Ph.D., and colleagues have developed a cell line to address the challenges facing cellular modeling of disease. The study, published in Cell Stem Cell, details genetic properties characterization of eight iPSC lines, with one rising above the rest. 

    The cell line KOLF2.1J proved to be an all-around well-performing iPSC line with high genomic stability in post-edited clones. Meeting all the criteria for cellular engineering research, KOLF2.1J can act as a stable foundation for modeling hundreds of genetic alterations relevant to Alzheimer’s disease, rare disease, cancer, and more.

    Through the partnership between the iPSC Neurodegenerative Disease Initiative and the Chan Zuckerberg Initiative, KOLF2.1J is available as both a reference parental line and with selected single nucleotide variants (SNVs) as part of the catalog of human iPSCs at JAX. 

    By selecting KOLF2.1J as a cell line of choice, researchers will be able to generate consistent, integratable data and help accelerate human disease research. In collaboration with UConn Health, Skarnes and fellow JAX researchers are now planning to derive additional similarly well-characterized iPSC lines from healthy individuals of diverse genetic backgrounds.

    About The Jackson Laboratory

    The Jackson Laboratory is an independent, nonprofit biomedical research institution with a National Cancer Institute-designated Cancer Center and nearly 3,000 employees in locations across the United States (Maine, Connecticut, California) and Japan, as well as a joint venture in China. Its mission is to discover precise genomic solutions for disease and empower the global biomedical community in the shared quest to improve human health. For more information, please visit www.jax.org​​​​​​​.

    [ad_2]

    Jackson Laboratory

    Source link

  • Measles virus ‘cooperates’ with itself to cause fatal encephalitis

    Measles virus ‘cooperates’ with itself to cause fatal encephalitis

    [ad_1]

    Newswise — Fukuoka, Japan—Researchers in Japan have uncovered the mechanism for how the measles virus can cause subacute sclerosing panencephalitis, or SSPE, a rare but fatal neurological disorder that can occur several years after a measles infection.

    Although the normal form of the measles virus cannot infect the nervous system, the team found that viruses that persist in the body can develop mutations in a key protein that controls how they infect cells. The mutated proteins can interact with its normal form, making it capable of infecting the brain. Their findings were reported in the journal Science Advances.

    If you are of a certain age, you may have gotten the measles as a child. Many born after the 1970s have never gotten it thanks to vaccines. The condition is caused by the virus of the same name, which is one of the most contagious pathogens to this day. The World Health Organization estimates that nearly nine million people worldwide were infected with measles in 2021, with the number of deaths reaching 128,000.

    “Despite its availability, the recent COVID-19 pandemic has set back vaccinations, especially in the Global South,” explains Yuta Shirogane, Assistant Professor at Kyushu University’s Faculty of Medical Sciences. “SSPE is a rare but fatal condition caused by the measles virus. However, the normal measles virus does not have the ability to propagate in the brain, and thus it is unclear how it causes encephalitis.”

    A virus infects cells through a series of proteins that protrude from its surface. Usually, one protein will first facilitate the virus to attach to a cell’s surface, then another surface protein will cause a reaction that lets the virus into the cell, leading to an infection. Therefore, what a virus can or cannot infect can depend heavily on the type of cell.

    “Usually, the measles virus only infects your immune and epithelial cells, causing the fever and rash,” continues Shirogane. “Therefore, in patients with SSPE, the measles virus must have remained in their body and mutated, then gained the ability to infect nerve cells. RNA viruses like measles mutate and evolve at very high rates, but the mechanism of how it evolved to infect neurons has been a mystery.”

    The key player in allowing the measles virus to infect a cell is a protein called fusion protein, or F protein. In the team’s previous studies, they showed that certain mutations in the F protein puts it in a ‘hyperfusongenic’ state, allowing it to fuse onto neural synapses and infect the brain.

    In their latest study, the team analyzed the genome of the measles virus from SSPE patients and found that various mutations had accumulated in their F protein. Interestingly, certain mutations would increase infection activity while others actually decreased it.

    “This was surprising to see, but we found an explanation. When the virus infects a neuron, it infects it through ‘en bloc transmission,’ where multiple copies of the viral genome enter the cell,” continues Shirogane. “In this case, the genome encoding the mutant F protein is transmitted simultaneously with the genome of the normal F protein, and both proteins are likely to coexist in the infected cell.”

    Based on this hypothesis, the team analyzed the fusion activity of mutant F proteins when normal F proteins were present. Their results showed that fusion activity of a mutant F protein is suppressed due to interference from the normal F proteins, but that interference is overcome by the accumulation of mutations in the F protein.

    In another case, the team found that a different set of mutations in the F protein results in a completely opposite result: a reduction in fusion activity. However, to their surprise, this mutation can actually cooperate with normal F proteins to increase fusion activity. Thus, even mutant F proteins that appear to be unable to infect neurons can still infect the brain.

    “It is almost counter to the ‘survival of the fittest’ model for viral propagation. In fact, this phenomenon where mutations interfere and/or cooperate with each other is called ‘Sociovirology.’ It’s still a new concept, but viruses have been observed to interact with each other like a group. It’s an exciting prospect” explains Shirogane.

    The team hopes that their results will help develop therapeutics for SSPE, as well as elucidate the evolutionary mechanisms common to viruses that have similar infection mechanisms to measles such as novel coronaviruses and herpesviruses.

    “There are many mysteries in the mechanisms by which viruses cause diseases. Since I was a medical student, I was interested in how the measles virus caused SSPE. I am happy that we were able to elucidate the mechanism of this disease,” concludes Shirogane.

    ###

    For more information about this research, see “Collective fusion activity determines neurotropism of an en bloc transmitted enveloped virus” Yuta Shirogane, Hidetaka Harada, Yuichi Hirai, Ryuichi Takemoto, Tateki Suzuki, Takao Hashiguchi, Yusuke Yanagi, https://doi.org/10.1126/sciadv.adf3731

    About Kyushu University
    Kyushu University is one of Japan’s leading research-oriented institutes of higher education since its founding in 1911. Home to around 19,000 students and 8,000 faculty and staff, Kyushu U’s world-class research centers cover a wide range of study areas and research fields, from the humanities and arts to engineering and medical sciences. Its multiple campuses—including the largest in Japan—are located around Fukuoka City, a coastal metropolis on the southwestern Japanese island of Kyushu that is frequently ranked among the world’s most livable cities and historically known as a gateway to Asia.

    [ad_2]

    Kyushu University

    Source link

  • When bugs swipe left

    When bugs swipe left

    [ad_1]

    Newswise — It’s almost Valentine’s Day, and love is in the air. Or in the waxy coating on your skin, if you are a vinegar fly. That’s where flies encounter pheromones that play an important role in regulating sexual attraction.

    Flies use pheromones to ensure that they court and mate with members of the same species. As new fly species split off from a common ancestor, but continue to share the same environment, they need a way to rapidly diversify their pheromones to suppress inter-species mating. When members of two related species stop finding each other attractive, this helps prevent interbreeding.

    But it’s more complicated than “she loves me, she loves me not.

    Because the perception and production of pheromones are mediated by different tissues and cellular pathways, evolving new mating pheromones requires a coordinated evolution of both the genes responsible for sensing the pheromones as well as the genes that produce them.

    A new study in iScience led by Yehuda Ben-Shahar at Washington University in St. Louis identifies a link between the genetic instructions for the production and perception of sex pheromones. The research was conducted in collaboration with Jocelyn Millar from the University of California, Riverside.

    Researchers reported that a single protein called Gr8a is expressed in different organs in male and female flies and appears to play an inhibitory role in mating decision-making. The findings point to one of the ways that flies could put up behavioral barriers to protect against mating with the wrong kind of partner.

    “Mating pheromones often show rapid evolution,” said Ben-Shahar, a professor of biology in Arts & Sciences. “Because pheromonal communication requires a very robust and specific structural recognition of chemicals used as pheromones by the proteins that bind them in sensory neurons (chemoreceptors), it means that major molecular changes in either the receptor or the pheromone would reduce sexual attraction between males and females.”

    Ben-Shahar and his team found that Gr8a was expressed in tissues in fly mouthparts, including the proboscis, as well as in taste neurons in the forelegs of both males and females. They also found Gr8a in cells in the abdomens of males. This was important because it provided Ben-Shahar and his team the first hint that a gene that had been previously identified as a sensory chemoreceptor must also have non-neuronal functions.

    “Our findings provide a relatively simple molecular explanation for how signal production and perception are tied together in vinegar flies,” Ben-Shahar said. “A single pleiotropic protein can function as both a receptor for pheromones in sensory neurons, as well as contribute to their production in the pheromone-producing cells (oenocytes) of males, by way of a less-understood process.”

    In one of the experiments that Ben-Shahar and his team conducted, the scientists took flies that were mutant for the Gr8a receptor and reconstituted them using input from a different vinegar fly species. This experiment showed that introducing Gr8a from another species was enough to change the overall pheromone profile of the animal.

    The scientists still have not pinpointed exactly how the chemoreceptor affects the way the signal is produced, but they do know that it causes quantitative and qualitative differences in pheromones. And even small changes in pheromones could be enough to keep closely related flies from finding each other attractive — and change their mate choice behaviors.

    The question of how closely related species evolve and maintain behavioral mating barriers is one that has implications for several different basic and applied biological research fields.

    “Based on what we have observed, mutations in a single gene could provide a molecular path for a pheromonal communication system to evolve while still maintaining the functional coupling between a pheromone and its receptor,” Ben-Shahar said. “Our research uncovers a potential avenue for pheromonal systems to rapidly evolve when new species arise.”

    This work was supported by National Science Foundation grants 1322783, 1754264 and 1707221, and National Institutes of Health (NIH) grant NS089834.

    [ad_2]

    Washington University in St. Louis

    Source link